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Angiotensin-(1–7), an active fragment of both angiotensins I
and II, generally opposes the vascular and proliferative
actions of angiotensin II. Here we evaluated effects of the
angiotensin-(1–7) receptor Mas on renal physiology and
morphology using Mas-knockout mice. Compared to the
wild-type animals, Mas knockout mice had significant
reductions in urine volume and fractional sodium excretion
without any significant change in free-water clearance. A
significantly higher inulin clearance and microalbuminuria
concomitant with a reduced renal blood flow suggest that
glomerular hyperfiltration occurs in the knockout mice.
Histological analysis found reduced glomerular tuft diameter
and increased expression of collagen IV and fibronectin in
the both the mesangium and interstitium, along with
increased collagen III in the interstitium. These fibrogenic
changes and the renal dysfunction of the knockout mice
were associated with an upregulation of angiotensin II AT1
receptor and transforming growth factor-b mRNA. Our study
suggests that Mas acts as a critical regulator of renal
fibrogenesis by controlling effects transduced through
angiotensin II AT1 receptors in the kidney.
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The renin–angiotensin system (RAS) is classically conceived
as a coordinated hormonal cascade in the control of
cardiovascular, renal, and adrenal functions, mainly through
the actions of Angiotensin (Ang)II.1 Recent advances in cell
and molecular biology have led to the recognition of other
active fragments of RAS metabolism, such as Ang III, Ang IV,
and Ang-(1–7),2–4 the Ang IV insulin-regulated aminopepti-
dase-binding site,5 the angiotensin-converting enzyme
(ACE)2, a homolog of classic ACE that forms Ang-(1–7)
directly from Ang II and indirectly from Ang I,6,7 and the
G-protein-coupled receptor Mas.8
In general, Ang-(1–7) opposes the vascular and prolif-
erative effects of Ang II and exerts complex renal actions in
chronic renal diseases and hypertension.3,9,10 Ang-(1–7) is
formed from Ang II by prolylendopeptidase, prolyl-carboxy-
peptidase or ACE2, or directly from Ang I through hydrolysis
by prolylendopeptidase and endopeptidase 24.11 and is
metabolized by ACE to Ang-(1–5).6,7 ACE inhibitors elevate
Ang-(1–7) concentrations by both increasing Ang I, a
substrate for Ang-(1–7) generation, and preventing Ang-
(1–7) degradation.2–4 Recent studies suggest that, at least in
part, the beneficial effects of ACE inhibitors11,12 and AT1
receptor blockade13 may be attributed to Ang-(1–7). These
findings are in keeping with the hypothesis that the RAS is
capable of self-regulating its activity through the formation
of Ang-(1–7).2–4 Furthermore, Kostenis et al14 showed that
receptor Mas can hetero-oligomerize with AT1 and, by so
doing, inhibit the actions of Ang II. Indeed, Mas acts in vitro
as an antagonist of the AT1 receptor.
15
Our group showed that deletion of Mas produces an
impairment in cardiac function associated with a significant
increase in collagen I, III, and fibronectin in the heart.16 The
aim of this study was to evaluate the role of Mas in kidney
structure and function using mice with genetic deletion of
this receptor.
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RESULTS
Renal function parameters
As the results displayed in Table 1 the 24-h urine flow of
Mas/ animals was significantly lower in comparison with
that of Masþ /þ . However, no differences in blood glucose
levels and in water and food intake were observed. The
reduced urinary volume observed in Mas/ mice was
accompanied by a significant increase in urinary osmolality
and a decrease in the fractional excretion of sodium (Po0.05,
Table 1). Despite the increase in urinary osmolality, plasma
osmolality, osmolal, and free-water clearance were un-
changed in Mas/ animals when compared with those in
Masþ /þ mice. No changes were detected in the fractional
excretion of potassium either. Mean arterial pressure (MAP)
in Mas/ mice was also undistinguished from that in Masþ /þ
animals. However, significant reductions of renal blood flow
accompanied by increased total renal vascular resistance were
detected in knockout mice. Despite the reduced renal blood
flow, Mas/ animals presented a significant elevation in the
glomerular filtration rate (GFR), estimated by the creatinine
and inulin clearances. This finding was made along with an
elevated urinary albumin excretion in Mas/ mice (Po0.05,
Table 1).
Renal structure
The wet weights of kidneys from Masþ /þ and Mas/
animals normalized for body weight (BW) were similar
(Table 2). However, microscopic changes in the kidney
structure of Mas/ mice were observed, including a
significant reduction in the diameters of the glomerular tuft
and Bowman’s capsule in comparison with those in Masþ /þ
animals (Figure 1 and Table 2). Bowman’s spaces and the
diameter of the cortical tubule were unaltered in Mas/
animals when compared with those in Masþ /þ mice.
Renal tissue analysis by confocal microscopy revealed that
the fluorescence of many extracellular matrix proteins was
significantly higher in the cortex and medulla of Mas/
kidneys when compared with those in Masþ /þ (Figures 2
and 3). Mas/ kidneys exhibited a significant increase in
collagen III in the cortex (9.08±1.63 versus 1.83±0.77
arbitrary units in Masþ /þ mice, Po0.05, Figure 2) as well as
in the medulla (3.60±0.79 versus 0.26±0.05 arbitrary units
in Masþ /þ mice, Po0.05, Figure 3). Similar results were
obtained with collagen IV and fibronectin. Kidneys from
Mas/ animals presented higher levels of both extracellular
matrix proteins than did Masþ /þ kidneys in the renal cortex
(collagen IV: 8.49±0.61 versus 6.49±0.43 arbitrary units
and fibronectin: 11.22±2.40 versus 4.07±0.47 arbitrary
units, Po0.05 for both comparisons, Figure 2) and medulla
(collagen IV: 18.98±1.11 versus 10.70±0.84 arbitrary units
and fibronectin: 21.56±2.71 versus 11.04±2.24 arbitrary
Table 1 | General measurements and renal function
parameters in Mas+/+ and Mas/ mice
Parameters Mas+/+ Mas/
Body weight (g) 25.7±0.5 25.7±0.6
Blood glucose (mg per 100 ml) 116.8±3.9 111.8±3.2
Daily food intake (g) 5.18±0.25 5.69±0.27
Daily water intake (ml) 6.37±0.34 5.90±0.32
Daily urine volume (ml) 1.65±0.19 1.07±0.14*
Mean arterial pressure (mm Hg) 80.22±1.78 78.75±2.23
RBF (ml/min per g) 19.16±4.09 10.76±1.39*
RVR (mm Hg ml/min per g) 5.39±1.20 8.25±1.07*
Creatinine clearance (ml/min per g) 1.80±0.39 3.20±0.50*
Inulin clearance (ml/min per g) 2.54±0.49 4.61±0.74*
Microalbuminuria (mg per 24 h) 0.03±0.01 0.20±0.07*
Urine osmolality (mOsm/kg H2O) 3245±196 4030±330*
Serum osmolality (mOsm/kg H2O) 275±7 273±5
Osmolal clearance (ml/min) 10.2±0.8 9.1±0.8
Free water clearance (ml/min) 9.2±0.7 8.4±0.7
Serum sodium (mmol/l) 149±2 147±2
Sodium FE (%) 1.05±0.14 0.38±0.05*
Serum potassium (mmol/l) 4.8±0.4 5.1±0.4
Potassium FE (%) 15.5±3.5 15.3±5.6
FE, fractional excretion; RBF, renal blood flow; RVR, renal vascular resistance. Values
are mean±s.e.m. *Po0.05. Data were analyzed by unpaired Student’s t-test.
Table 2 | Morphological parameters in Mas+/+ and Mas/
mice
Parameters Mas+/+ Mas/
Kidney index (mg/g of body weight) 6.0 (5.6–6.4) 5.9 (5.5–6.3)
Cortical tubule diameter (mm) 32.5 (30.0–37.5) 32.5 (30–37.5)
Bowman’s capsule diameter (mm) 62.5 (57.5–70.0) 57.5 (52.5–62.5)*
Glomerulus tuft diameter (mm) 57.5 (52.5–62.5) 50.0 (47.5–55.0)*
Bowman’s space diameter (mm) 6.0 (5.7–6.3) 6.1 (5.8–6.3)
Values are medians (25 and 75% percentile), *Po0.05. Data were analyzed by the
Mann–Whitney test.
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Figure 1 | Kidney architecture in Masþ /þ and Mas/ mice.
Kidney sections showing reduced Bowman’s capsule and
glomeruli tuft in Mas/ mice in comparison with Masþ /þ
controls (Masson’s trichrome,  400).
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units, Po0.05 for both comparisons, Figure 3). However, no
differences in the expression of collagen I in the cortex and
medulla were observed in the kidneys from Mas/ and
Masþ /þ animals (Figures 2 and 3). In the mesangium,
Mas/ kidneys exhibited a selective increase in collagen IV
(13.25±0.99 versus 10.07±0.60 arbitrary units in Masþ /þ
mice, Po0.05) and fibronectin (29.43±4.17 versus
14.22±2.66 arbitrary units in Masþ /þ mice, Po0.05). In
contrast, collagen types I and III exhibited a similar pattern in
the mesangium in Mas/ and Masþ /þ kidneys (Figure 4).
As shown in Figure 5, results obtained with immunoblotting
confirmed the increased levels of fibronectin and collagen
types III and IV in Mas/ animals.
Distribution of Mas in the kidney
To determine the distribution of Mas in the kidneys, confocal
immunofluorescence analysis of renal tissue from Masþ /þ
mice was performed. Mas immunolabeling was detected in
different segments of the nephron, such as the juxtaglomer-
ular apparatus, proximal cortical tubules, and collecting
ducts (Figure 6).
AT1 receptor and TGF-b RNA expression in the kidney
As observed in Figure 7, real-time PCR revealed a threefold
increase in RNA expression of AT1 receptor and a twofold
elevation of total transforming growth factor-b (TGF-b)
RNA in kidneys from Mas/ mice compared with those in
Masþ /þ mice (2.65±0.29 versus 0.85±0.19 relative expres-
sion for AT1 RNA and 1.75±0.23 versus 0.85±0.17 relative
expression for TGF-b RNA, Po0.05 for both comparisons).
DISCUSSION
Genetic deletion of the Ang-(1–7) receptor Mas produces an
extremely rich phenotype that includes cardiac dysfunction,16
decreased baroreflex function, endothelial dysfunction,17
reduced reproductive function,18 increased thrombogen-
esis,19 and, depending on the genetic background, increased
blood pressure and marked changes in lipid and glycidic
metabolism, leading to a metabolic syndrome-like state.17,20
Phenotypic differences have been reported according to
genetic background. This is particularly true for blood
pressure and plasma glucose, which are increased in FVB/N
Mas/17,20 and are normal in C57BL/6 mice, as shown in
this study. These differences could be related to the fact that
C57BL/6 presents only one renin gene compared with two
genes of other mice strains, including FVB/N.21 However,
despite the potentially lower sensitivity to the genetic deletion
of Mas in C57BL/6 mice, we showed that Mas is critical for
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Figure 2 | Immunofluorescence of extracellular matrix (ECM)
proteins in the cortex of kidneys from Masþ /þ (left column) and
Mas/ (right column) mice. (a) Fluorescence (Cy3-labeled anti-
rabbit IgG) reveals the immunolabeling of ECM proteins. Expression of
type III collagen (Col III), type IV collagen (Col IV), and fibronectin (Fn)
were increased in the cortex of Mas/ compared with that of
Masþ /þ mice, whereas the expression of type I collagen (Col I)
was unaltered. (b) Quantification of ECM proteins in the cortex of
Masþ /þ and Mas/ mice. Data are shown as mean±s.e.m.
*Po0.05; **Po0.01. A.U. indicates arbitrary unit.
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the regulation of renal homeostasis even in young animals.
Our data suggest that the genetic deletion of Mas probably
leads to glomerular hypertension, and also produces
structural and molecular changes, which stimulates renal
fibrosis. Furthermore, the observed changes were not related
to arterial hypertension or to hyperglycemia.
The ability of the kidney to generate high concentrations
of Ang II and Ang-(1–7) allows it to regulate intrarenal levels
of these angiotensins in accordance with homeostatic needs
for the regulation of renal hemodynamics.22,23 In this
context, Mas-deficient mice presented significant changes in
renal hemodynamic and in glomerular filtration. When
compared with wild-type mice, Mas/ animals had lower
renal blood flow accompanied by elevated renal vascular
resistance. Both alterations occurred along with a 1.8-fold
increase in GFR according to creatinine as well as inulin
clearance measurements, and a 6.7-fold increase in urinary
albumin excretion. As blood pressure was similar in Mas/
and in wild-type animals, the increased GFR in conjunction
with reduced renal blood flow was probably because of
elevated vascular tonus in the efferent arterioles. Ang II
markedly raises efferent glomerular arteriolar resistance but
does not change afferent arteriolar resistance unless the renal
perfusion pressure rises.24 The consequence of the dispropor-
tionate increase in efferent (over afferent) resistance is a
marked increase in intraglomerular pressure. Thus, the Ang
II-induced decrease in renal plasma flow is offset by the
increase in mean transcapillary ultrafiltration pressure and
this maintains or even increases the GFR.22–25 Ang-(1–7)
directly and indirectly vasodilates afferent arterioles and
increases renal blood flow.26–28 Although the relative role of
each angiotensin on glomerular hemodynamics is still
unknown, our results indicated that Ang-(1–7) may act as a
physiological regulator of intraglomerular pressure by
opposing the glomerular hypertensive effects of Ang II.
Therefore, without the physiological antagonism of Ang-
(1–7), intrarenal and/or plasma Ang II, acting on higher
expressed AT1 receptors, might increase efferent arteriolar
resistance and glomerular filtration pressure, thus contribut-
ing to glomerular capillary hypertension.
Mas-knockout animals also exhibited lower urinary
volume accompanied by sodium retention without BW gain
when compared with controls. As young Mas/ mice (9–10
weeks of age) were used, it would be possible that the
persistence of these alterations could lead to edema and BW
elevations in older animals. Moreover, no changes in serum
osmolality, osmolal, or free-water clearance were observed,
indicating that fluid retention reflects a direct effect on
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Figure 3 | Immunofluorescence of extracellular matrix (ECM)
proteins in the medulla of kidneys from Masþ /þ (left column)
and Mas/ (right column) mice. (a) Fluorescence (Cy3-labeled
anti-rabbit IgG) reveals the immunolabeling of ECM proteins.
Expression of type III collagen (Col III), type IV collagen (Col IV),
and fibronectin (Fn) were increased in the medulla of Mas/
compared with that of Masþ /þ mice, whereas the expression of
type I collagen (Col I) was unaltered. (b) Quantification of ECM
proteins in the medulla of Masþ /þ and Mas/ mice. Data are
shown as mean±s.e.m. *Po0.05; **Po0.01. A.U. indicates
arbitrary unit.
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sodium handling without significant changes in water
transport.29 These alterations are in agreement with the
tubular effects of Ang II.25 Through efferent arteriolar
vasoconstriction, Ang II causes changes in peritubular
capillary dynamics that could increase renal tubular fluid
reabsorption.24,25 In addition, Ang II significantly stimulates
proximal and distal sodium reabsorption through the
activation of AT1 receptors.
22,23 Although further experi-
ments with AT1 blockade would be helpful, our findings
suggest that ACE–Ang II–AT1 axis could influence the
direction of renal tubular changes detected in Mas/ mice.
The major morphological alterations found in kidneys
from young Mas/ animals were a reduction in glomerular
tuft diameter and an increased expression of collagen III, IV,
and fibronectin in the kidney interstitium as well as of
collagen IV and fibronectin in the mesangium. Despite the
presence of matrix proteins deposition in kidneys of Mas/
mice, we did not observe the classical findings of glomerular
hypertension, such as glomerular hyperthrophy. However, as
this study reflected only a time point after Mas deletion (9- to
10-week-old mice), we were not able to show dynamic
changes in glomerular size. Glomerular hypertrophy may not
be evident in young animals. Similarly, the kidneys of young
(3-month-old) mice with the deletion of ACE2 gene showed
no gross abnormalities having normal architecture of the
cortex and medulla, comparable with those of age-matched
wild-type mice. However, electron microscopy of these mice
evidenced mesangial injury with small foci of collagen
deposition suggestive of an early disease process.30 We also
cannot rule out the possibility that the genetic deletion of
Mas could interfere with fetal glomerular development by
producing smaller glomerulus than that of wild-type animals.
Consequently, even if glomerular hypertrophy has occurred
in Mas/ mice, it might not be detected. Further studies are
obviously necessary to clarify the time course of histological
glomerular changes in Mas/ animals. In addition, changes
in glomerular permeability, not evaluated in this study, may
be also involved in the glomerular dysfunction present in
Mas/ mice.
Our earlier studies have indicated a role for the Ang-
(1–7)–Mas interaction in the regulation of matrix proteins
deposition in the heart and liver.16,31 In this study, we showed
the fibronectin and collagen III deposition in the kidney of
young Mas/ mice, suggesting an initial fibrogenic process.
Accordingly, in the initial stages of collagen deposition and
renal fibrosis, type III collagen appears in greater amounts
than do type I.32,33 As fibrogenesis progresses, there is a
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Figure 4 | Immunofluorescence of extracellular matrix (ECM)
proteins in the mesangium of kidneys from Masþ /þ (left
column) and Mas/ (right column) mice. (a) Fluorescence (Cy3-
labeled anti-rabbit IgG) reveals the immunolabeling of ECM
proteins. Expression of type IV collagen (Col IV) and fibronectin
(Fn) was increased in the mesangium of Mas/ compared with
Masþ /þ mice, whereas the expression of type I collagen (Col I)
and type III collagen (Col III) was unaltered. (b) Quantification of
ECM proteins in the mesangium of Masþ /þ and Mas/ mice.
Data are shown as the mean±s.e.m. *Po0.05; **Po0.01. A.U.
indicates arbitrary unit.
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proportional decrease in type III collagen, and tubulointer-
stitial fibroblasts secrete collagen types I, III, IV, and V in
response to TGF-b, epidermal growth factor, and interleukin-
2.32,33 Several studies have shown the involvement of the Ang
II–AT1 axis in profibrotic mechanisms.
34–38 Ang II is the key
mediator of many processes involved in glomerulosclerosis,
affecting blood pressure, glomerular hemodynamics, and
matrix proteins deposition.38 Moreover, the improvement in
renal function and the regression of renal fibrosis during RAS
antagonism largely involve a decreased collagen expression
mediated by the Ang II–TGF-b pathway, but other mechan-
isms may also play a role.38–42
Although a protective role for Ang-(1–7) in renal fibrosis
remains speculative, we provide strong evidence for such a
role by showing alterations in renal structure because of the
absence of Mas. In this regard, many studies have shown that
Ang-(1–7) exerts inhibitory effects on vascular and cellular
growth mechanisms.31,43–46 The molecular mechanisms for
the antiproliferative response to Ang-(1–7) include the
stimulation of prostaglandin and cAMP production as well
as the inhibition of mitogen-activated protein (MAP)
kinases.45 Mas seems to mediate the antiproliferative effect
of Ang-(1–7) in vascular smooth muscle cells,43 liver tissue,31
and cardiomyocytes.47 Moreover, Mas-deficient mice
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Figure 5 | Immunoblotting of extracellular matrix (ECM) proteins in kidneys of Masþ /þ and Mas/ animals. (a) Immunoblotting
shows no difference of Collagen I expression in Masþ /þ and Mas/ mice kidneys. Significant increases in (b) Collagen III, (c) Collagen IV,
and (d) fibronectin expression were detected by comparing immunoblots of Mas/ mouse kidneys with those of Masþ /þ controls. Each
band represents one mouse kidney from either Masþ /þ or Mas/ mice. Data are shown as the mean±s.e.m. *Po0.05. A.U. indicates arbitrary
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Figure 6 | Immunofluorescence of Mas receptor in the kidney of Mas+/+ control mice. Fluorescence (Cy3-labeled anti-rabbit IgG) reveals
the immunolabeling of Mas antibody in kidney tissue.
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exhibited an impairment of heart function associated with
changes in collagen expression toward a profibrotic profile.16
Gallagher and Tallant46 also reported the inhibition of
human lung cell growth by Ang-(1–7) through a reduction
in the serum-stimulated phosphorylation of extracellular
signal-regulated kinase (ERK) 1 and ERK2. As the ERK
cascade is activated in response to different stimuli, such as
growth factors, cytokines, or DNA-damaging agents, the
stimulation of the ACE2–Ang-(1–7)–Mas axis could be
effective in halting glomerulosclerosis. Su et al48 have
reported that Ang-(1–7) inhibits Ang II-stimulated MAP
kinases phosphorylation in proximal tubular cells. Thus, the
generation of Ang-(1–7) by proximal tubular ACE2 could
counteract the proliferative effects of locally produced
Ang II.48 In keeping with this possibility, recent studies
suggested a protective role for ACE2 in the kidney.30,49–52
Kidney diseases have been associated with a reduction in
renal ACE2 expression, possibly facilitating the damaging
effects of Ang II.30,49–52 Acquired or genetic ACE2 deficiency
also appears to exacerbate renal damage and albuminuria in
experimental models, supporting this hypothesis.30,50–52 In
addition, chronic blockade of ACE2 with the enzyme
inhibitor, MLN-4760, in control or diabetic mice produced
albuminuria and matrix proteins deposition.52 Taken
together, these findings suggest that a decrease in ACE2
may be involved in kidney disease, possibly by disrupting the
metabolism of angiotensin peptides. It is not clear yet,
however, whether this effect is because of degradation of Ang
II, formation of Ang-(1–7), or presumably both.
Angiotensin II clearly exerts a key role in the progression
of renal diseases, justifying the use of RAS inhibition to
reduce the rate of renal function loss and to ameliorate renal
fibrosis.53,54 Clinical studies have shown that ACE inhibitors
and AT1 receptor antagonists delay the progression of chronic
kidney disease to end-stage renal disease.1,53–56 It should be
mentioned that Ang-(1–7) levels have significantly increased
during chronic treatment with ACEIs or AT1 blockers.
10,13
However, the cellular and molecular mechanisms involved in
RAS inhibition are not fully understood. In this regard, we
also found an increased expression of AT1 receptor and TGF-
b RNA in Mas knockout animals as compared with those in
controls. These results indicate a molecular deviation toward
a fibrogenic process because of the blunted activity of the
ACE2–Ang-(1–7)–Mas axis and an unopposed action of the
Ang II–AT1 axis at the renal level. Corroborating our
hypothesis, Kostenis et al14 suggest that Mas is a physiological
antagonist of the AT1 receptor. These authors also described
that Mas and AT1 can form a constitutive hetero-oligomeric
complex that is unaffected by the presence of agonists or
antagonists of both receptors.14 Moreover, mice lacking the
Mas gene showed enhanced Ang II-mediated vasoconstric-
tion in mesenteric microvessels in vivo.14
In summary, our findings suggest that the lack of Mas
produced a RAS imbalance leading to abnormal predomi-
nance of the ACE–Ang II–AT1 axis. Consequently, Mas
/
mice presented sodium and water retention, renal fibrosis
and inflammation, glomerular hyperfiltration, proteinuria,
and a tendency toward glomerulosclerosis. The ACE2–Ang-
(1–7)–Mas axis should be further investigated for the
treatment of renal fibrosis.
MATERIALS AND METHODS
Animals
Nine- to 10-week-old male C57BL/6 wild-type (Masþ /þ ) and
C57BL/6 Mas-knockout mice (Mas/) were obtained from the
transgenic animal facilities of our Institution. The study was
approved by our Ethics Committee.
General measurements and renal function parameters
To evaluate the effects of Mas deletion on renal physiology, Masþ /þ
(n¼ 18) and Mas/ (n¼ 17) mice were compared. The animals
were kept in a temperature-controlled room on a 14/10h-light/dark
cycle and housed in individual metabolic cages, with free access to
standard chow and tap water. After an adaptation period of 48 h,
urine volume, water, and food intake were measured for the next
24 h. At the end, 24h-urine samples were collected and centrifuged
at 3000 g for 5 min. Urine was used to determine osmolality,
microalbuminuria, sodium, potassium, and creatinine concentra-
tions. Blood samples were also obtained by decapitation and
centrifuged at 2000 g for 10 min. The resulting plasma was used to
measure osmolality, glucose, sodium, potassium, and creatinine
concentrations.
Sodium and potassium levels were measured by flame-photo-
metry (Barueri, SP, Brazil) (Celm FC-180, USA); creatinine
concentration was determined by an enzymatic kit (Labtest,
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Figure 7 | Total RNA expression of AT1 receptor and
transforming growth factor-b (TGF-b) in mouse kidneys. (a)
Relative expression of AT1 receptor RNA in the kidneys of Mas
þ /þ
and Mas/ mice. (b) Relative expression of TGF-b RNA in the
kidneys of Masþ /þ and Mas/ mice. Data are shown as
mean±s.e.m. *Po0.05.
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Belo Horizonte, MG, Brazil); glucose levels were measured by Accu-
Check glucometer (Roche Diagnostics, Indianapolis, IN, USA);
microalbuminuria was determined by a latex immunoassay (Gold
Analisa, Belo Horizonte, MG, Brazil); and osmolality was deter-
mined by a freezing-point osmometer (microOsmette, Calumet
City, IL, USA). Urinary fractional excretion of sodium and
potassium, osmolal clearance, free-water clearance, and creatinine
clearance were calculated.
To confirm the GFR estimated by creatinine clearance, plasma
inulin elimination kinetic was determined following a single bolus
injection of inulin57 in an additional group of Masþ /þ (n¼ 7) and
Mas/(n¼ 7) mice. The plasma inulin concentration was
measured at 5, 10, 20, and 45 min after bolus injection by the
antron method.58 Inulin clearance was analyzed by using one-
compartment model according to the formula: Inulin clearance¼ I/
(A/a), where I is inulin quantity, A is the y-intercept value of the
decay rate and a is the decay constant. A nonlinear regression curve-
fitting program (GraphPad Prism Software, USA) performed all
calculations.
Mean arterial pressure, renal blood flow, and total renal vascular
resistance were determined in an additional group of Masþ /þ
(n¼ 10) and Mas/ (n¼ 10) mice. MAP was recorded through a
femoral arterial catheter connected to a data acquisition system
(MP100-BIOPAC System Inc., Goleta, CA, USA). After 15 min of
baseline MAP record, renal blood flow was measured by the
fluorescent polystyrene microspheres (Molecular Probes, Invitrogen
Corporation, Carlsbad, CA, USA) technique.59–61 Briefly, two
different colors of 15 mm fluorescent microspheres were selected to
avoid spillover between colors.59 After mixing, 50,000 (50 ml)
fluorescent microspheres were infused into the left ventricle over
10 s. To calculate blood flow, arterial blood was withdrawn at a rate
of 0.25 ml/min through the right femoral artery for 55 s, starting 10 s
before microspheres injection. In the end, the animals were killed by
lethal anesthesia. Kidneys were then removed, weighed, and placed
in individual vials. Tissue and reference blood flow samples were
digested by 4 M ethanol-KOH and 2% Tween 80 solution and kept in
a hot bath (501C) overnight. The microspheres were then recovered
by the sedimentation method60 and the dye was extracted with 4 ml
of an organic solvent ethyl-acetate. The fluorescence intensity was
measured by luminescence spectrophotometry (Spex Fluoromax,
HORIBA Jobin Yvon Inc., Edison, NJ, USA) and renal blood flow
was calculated, as described earlier.59–61 The total renal vascular
resistance was calculated by the ratio between MAP and renal blood
flow of each animal.
Renal structure
To evaluate renal structure, histomorphometrical, immunohisto-
chemical, and immunoblotting analyses were performed on kidneys
from Masþ /þ (n¼ 4) and Mas/ (n¼ 4) mice.
Histomorphometry. Both kidneys of each animal were im-
mediately removed; mean wet weights were recorded and normal-
ized for BW (mg/g). Kidneys from each group were left in 4% Bouin
fixative for 24 h at room temperature. The tissues were dehydrated
by sequential washes with graded ethanol concentrations and
embedded in paraffin. Cross–sections (5mm) were cut from the
middle area of the kidney and stained with Masson’s trichrome. The
tissue sections were examined under light microscope (BX60,
Olympus, Center Valley, PA, USA) at  400 magnification and
photographed (Qcolor3, Olympus). The diameter of Bowman’s
capsule and the glomerular tuft from the glomerulus cut in vascular
pole planes (mean of 15 glomeruli per kidney) as well as the
diameter of the proximal cortical tubules (mean of 40 segments per
kidney) were analyzed using Image Pro-Express software.
Immunohistochemistry. Immunofluorescence-labeling and
quantitative confocal microscopy evaluated the distribution and
amount of collagen types I, III, IV, and fibronectin in Masþ /þ and
Mas/ mice kidneys. The same methodology was described earlier
for collagen I and III in human scars and normal skins.62 Briefly, the
kidneys were obtained from Masþ /þ and Mas/ mice, washed in
phosphate-buffered saline to eliminate blood, and cryofixed in 80%
methanol and 20% dimethyl-sulfoxide at 801C. The samples were
stored at 801C for 7 days, moved to 201C for 1 day, washed
thrice in 99.9% ethanol at room temperature, twice in xylene, and
then embedded in paraffin. Sections of 5–8 mm were mounted on
slides, deparaffinized with xylene, rehydrated through graded series
of ethanol to phosphate-buffered saline and then incubated in a
blocking solution (1% bovine serum albumin and 0.1% Tween 20)
at room temperature for 1 h. The sections were incubated overnight
at 41C with one of the following primary antibodies (Rockland
Immunochemicals Inc., Gilbertsville, PA, USA): rabbit anti-human
collagen I (1:200, cat. no. 600-401-103-0.5), rabbit anti-human
collagen III (1:200, cat. no. 600-401-105-0.1), rabbit anti-human
collagen IV (1:200, cat. no. 600-401-106-0.1), or rabbit anti-human
fibronectin (1:200, cat. no. 600-117-0.1). All antibodies were diluted
with blocking solution (1:10). After five rinses in phosphate-
buffered saline, donkey anti-rabbit IgG-conjugated with Cy3 (cat.
no. 711-165-152, Jackson Immunoresearch, West Grove, PA, USA)
was added for 1 h in the dark at room temperature. Following
washes with phosphate-buffered saline, the sections were mounted
in 90% glycerol/10% Tris 1 M, and images were captured through a
confocal microscope (Zeiss LSM 510, Carl Zeiss Inc., Go¨ttingen
Germany),  40 objective, and  400 original magnification. All
confocal settings were determined at the beginning of the imaging
session and remained unchanged. For quantitative analysis, the
images were captured at 8 bits and analyzed in a gray scale. Four
images were captured from each kidney region and three
measurements were obtained for each image. Scion Image Beta
4.02 software (Scion Corporation, NIH-USA) was used to quantify
fluorescence intensity and area. Background fluorescence was
subtracted from the region of interest. The intensity of fluorescence
corresponded to the unit ‘gray level,’ varying from 0 (black) to 255
(white), as an average of the area (sum of gray value of all pixels
divided by the number of pixels/area).
Immunoblotting. Equal amounts of protein (50mg) of each
kidney sample were prepared for electrophoresis with a sample buffer
NuPAGE LDS (Invitrogen Corporation, Carlsbad, CA, USA) plus 10%
b-mercaptoethanol, and incubated at 701C for 10 min. As described
earlier,63 the samples were loaded into bis-Tris NuPAGE 4–12% gels
(Invitrogen) and submitted to electrophoresis, followed by transfer to
nitrocellulose membranes (Hybond ECL, Amersham Pharmacia
Biotech, Chalfont St Giles, UK). Protein loading and efficiency of blot
transfer were monitored by staining with Ponceau S (Sigma Chemical,
St Louis, MO, USA). The membranes were blocked for 45 min with tris-
buffered saline 0.1%Tween-20 plus 5%non-fat milk. The membrane
blots were incubated overnight at 41C with the same antibodies used on
immunohistochemistry (anti-collagen I, 1:5000; anti-collagen III,
1:5000; anti-collagen IV, 1:1000; anti-fibronectin, 1:5000; and anti-b-
actin, 1:7000), diluted in tris-buffered saline 0.1% Tween-20. The
membranes were then washed and incubated for 1 h at room
temperature with horseradish peroxidase-conjugated secondary anti-
body, goat anti-rabbit IgG (1:15,000). The membranes were submitted
to chemiluminescent detection with ECL Plus (Amersham Biosciences,
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Chalfont St Giles, UK) and visualized on ImageQuant. Densitometric
analysis was carried out using Scion Image Beta 4.0.2 software.
Mas distribution in the kidney
Immunofluorescence analysis was carried out in four kidneys from
Masþ /þ mice to assess the localization of Mas. The same
procedures described earlier for immunofluorescence analysis of
extracellular matrix proteins were carried out to prepare the kidney
sections. Immunofluorescence labeling and quantitative confocal
microscopy were then carried out to determine the distribution of
Mas in renal tissue, using a specific Mas antibody (Novus
Biologicals, Littleton, CO, USA).
RNA expression for AT1 receptor and TGF-b
Total RNA expression of AT1 receptor and TGF-b in the kidney was
evaluated by retrotranscription and real-time PCR assays in five
animals of each group. Total RNA was prepared using the TRIzol
reagent (Invitrogen). RNA samples were reverse transcribed with
MML-V (Invitrogen). The endogenous hypoxanthine guanine
phosphoribosyltransferase (HPRT, internal control), AT1, and
TGF-b cDNA were amplified using specific primers and the SYBR
Green reagent (Applied Biosystem, Carlsbad, CA, USA) in an ABI
Prism 7000 platform (Applied Biosystem). AT1 primers: forward,
ATGGCTGGCATTTTGTCTGG; reverse, GTTGAGTTGGTCTCAGA
CAC. TGF-b primers: forward, GGTTCATGTCATGGATGGTGC;
reverse, TGACGTCACTGGAGTTGTAGGG. HPRT primers: for-
ward, GTTGGATACAGGCCAGACTTTGTT; reverse, GATTCAAC
TTGCGCTCATCTTAGGC.
Statistical analysis
Data were expressed as mean±s.e.m. or median. Values with
Gaussian distribution were analyzed using the unpaired Student’s
t-test. Non-Gaussian variables were expressed as medians and
compared using the Mann–Whitney test. Values of Po0.05 were
considered significant and adjusted by Bonferroni’s correction
according to the number of comparisons.
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